Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYR-322 add-on versus pioglitazone dose escalation in type 2 diabetes
NL-OMON31324Phase 3Withdrawn
- Sponsor
- Takeda
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alogliptin, pioglitazone and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Takeda. Primary endpoint: Glycemic control at Week 26 and Week 52. Planned start Mar 2007; status: withdrawn.
02
Drugs
alogliptinpioglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON31324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31324.